Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Gyre Therapeutics, Inc. (GYRE) Reports Q2 Loss, Beats Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of -50.00% and +10.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Cytokinetics (CYTK) Reports Q2 Loss, Beats Revenue Estimates
Cytokinetics (CYTK) delivered earnings and revenue surprises of +7.98% and +40.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
New Strong Sell Stocks for May 27th
GYRE, FSUN and AKZOY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2026.
Zacks
Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue Estimates
Gyre Therapeutics, Inc. (GYRE) delivered earnings and revenue surprises of +16.67% and -33.59%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Gyre Therapeutics (NASDAQ:GYRE) Trading Up 2% - Should You Buy?
Gyre Therapeutics (NASDAQ:GYRE) Trading 2% Higher - Here's What Happened...
MarketBeat
Gyre Therapeutics (GYRE) to Release Earnings on Tuesday
Gyre Therapeutics (NASDAQ:GYRE) will be releasing its Q4 2025 earnings before the market opens on Tuesday, March 31. (View Earnings Report at...
MarketBeat
Zacks Research Downgrades Gyre Therapeutics (NASDAQ:GYRE) to Strong Sell
Zacks Research lowered shares of Gyre Therapeutics from a "hold" rating to a "strong sell" rating in a report on Monday...
MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Time to Sell?
Gyre Therapeutics (NASDAQ:GYRE) Trading Down 8.2% - Should You Sell...
MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results
Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) posted its earnings results on Thursday. The company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.08 by ($0.04). The...
MarketBeat
Gyre Therapeutics (NASDAQ:GYRE) Downgraded by Wall Street Zen to Hold
Wall Street Zen cut Gyre Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat

Advertisement|Remove ads.